Jianmin Pharmaceutical Group Co.,Ltd. (SHA:600976)
China flag China · Delayed Price · Currency is CNY
32.04
+0.32 (1.01%)
Apr 29, 2026, 3:00 PM CST

SHA:600976 Ratios and Metrics

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
4,9155,1506,3949,9167,55111,989
Market Cap Growth
-30.78%-19.46%-35.52%31.31%-37.01%207.81%
Enterprise Value
3,9034,1635,5319,1316,67211,258
Last Close Price
32.0433.5740.8062.5246.9073.07
PE Ratio
14.5714.3117.6519.0218.5039.27
Forward PE
-15.2515.2515.2515.2515.25
PS Ratio
1.471.531.822.352.073.63
PB Ratio
1.781.922.614.394.058.06
P/TBV Ratio
1.811.962.664.474.138.28
P/FCF Ratio
20.7129.6256.1048.6351.0662.52
P/OCF Ratio
14.2318.7627.2936.9534.9848.36
EV/Sales Ratio
1.161.241.582.171.833.41
EV/EBITDA Ratio
14.8815.8837.7826.3822.6247.72
EV/EBIT Ratio
18.0218.5449.5629.1625.3954.27
EV/FCF Ratio
16.4423.9548.5344.7845.1158.71
Debt / Equity Ratio
0.040.050.070.050.030.05
Debt / EBITDA Ratio
0.360.471.150.320.180.30
Debt / FCF Ratio
0.400.721.540.560.360.37
Net Debt / Equity Ratio
-0.37-0.40-0.38-0.39-0.43-0.52
Net Debt / EBITDA Ratio
-4.05-4.11-6.43-2.56-2.74-3.26
Net Debt / FCF Ratio
-4.35-6.20-8.26-4.34-5.46-4.01
Asset Turnover
0.750.770.831.111.161.25
Inventory Turnover
4.214.404.565.607.068.34
Quick Ratio
1.281.361.201.181.161.17
Current Ratio
1.551.581.491.491.501.41
Return on Equity (ROE)
12.86%14.25%15.63%25.39%24.22%21.77%
Return on Assets (ROA)
3.02%3.19%1.65%5.14%5.22%4.92%
Return on Invested Capital (ROIC)
12.24%13.50%7.26%23.62%27.42%25.02%
Return on Capital Employed (ROCE)
7.50%8.00%4.40%13.50%13.80%13.50%
Earnings Yield
6.86%6.99%5.67%5.26%5.40%2.55%
FCF Yield
4.83%3.38%1.78%2.06%1.96%1.60%
Dividend Yield
2.84%2.68%2.21%1.92%2.13%1.10%
Payout Ratio
41.70%39.27%51.83%29.95%30.39%19.20%
Buyback Yield / Dilution
-1.17%0.23%0.49%-0.43%-0.26%1.35%
Total Shareholder Return
1.67%2.91%2.69%1.49%1.87%2.45%
Source: S&P Global Market Intelligence. Standard template. Financial Sources.